TurnerTrends Stock Rating Report for ALNY
Data valid for week beginning July 21, 2008
|
ALNY [News]
|
Alnylam Pharmaceuticals Inc
|
Company Profile
"Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, develops therapeutics based on RNA interference (RNAi). Its lead RNAi therapeutic program includes ALN-RSV01, a phase II human clinical trial product for the treatment of respiratory syncytial virus (RSV) infection. The company's therapeutic programs in pre-clinical development stage comprise ALN-PCS for the treatment of hypercholesterolemia- ALN-VSP for the treatment of liver cancer- and ALN-HTT for the treatment of Huntington's disease. It also has a range of discovery programs for RNAi therapeutics for the treatment of various diseases, including viral hemorrhagic fever that comprise the Ebola virus- progressive multifocal leukoencephalopathy- pandemic flu- Parkinson's disease- and cystic fibrosis. It has strategic alliances with Medtronic, Inc.- Novartis Pharma AG- and Biogen Idec, Inc. for the development and commercialization of RNA interference system products. Alnylam Pharmaceuticals also has license agreements with biotechnology companies, which engage in developing RNAi therapeutic products- and research companies that commercialize RNAi reagents or services. In addition, the company has collaboration agreements with Medtronic, Inc. for the development of drug-device products for the treatment of neurodegenerative diseases- Novartis Pharma AG to develop RNAi therapeutics for pandemic flu- University of Texas Southwestern to develop RNAi therapeutics targeting proprotein convertase subtilisn-kexin type 9- and Inex Pharmaceuticals Corporation for the discovery, development, and commercialization of lipid-based nanoparticle formulations for the delivery of RNAi therapeutics, as well as a joint venture with ISIS Pharmaceuticals, Inc. focused on the discovery, development, and commercialization of microRNA (miRNA) therapeutics. It also has an alliance with Kyowa Hakko Kogyo Co., Ltd. to develop and commercialize ALN-RSV01. The company was founded in 2002 and is based in Cambridge, Massachusetts."
|
Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
|
|
|
Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
|
|
Latest News
| Wed, 23 Jul 2008 10:54:10 Etc/GMT | Roche gets Arius in biotech buying moves (AP) | | Tue, 22 Jul 2008 11:45:11 Etc/GMT | Roche buys Mirus Bio Corp. for $125 million (AP) | | Tue, 22 Jul 2008 05:53:29 Etc/GMT | UPDATE - Roche acquires private US RNAi company for $125 mln (at Reuters) | | Mon, 21 Jul 2008 21:01:40 Etc/GMT | Alnylam Continues Signing Deals (Zacks.com) | | Mon, 21 Jul 2008 12:00:00 Etc/GMT | Alnylam Grants New InterfeRx(TM) Intellectual Property License to Calando for Development and Commercialization of RNAi Therapeutics (Business Wire) | | Thu, 17 Jul 2008 20:31:09 Etc/GMT | ALNYLAM PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (EDGAR Online) | | Wed, 16 Jul 2008 21:14:23 Etc/GMT | Health Winners & Losers: St. Jude (at TheStreet.com) | | Wed, 16 Jul 2008 15:45:12 Etc/GMT | Alnylam and Novartis extend RNAi partnership (at bizjournals.com) | | Wed, 16 Jul 2008 10:34:00 Etc/GMT | Alnylam Announces Extension of RNAi Therapeutics Collaboration with Novartis (Business Wire) | | Tue, 15 Jul 2008 20:15:09 Etc/GMT | Dicerna Series A funding up to $21.4 million (at bizjournals.com) | | Fri, 11 Jul 2008 23:04:17 Etc/GMT | Health Winners & Losers: Momenta (at TheStreet.com) | | Fri, 11 Jul 2008 22:31:11 Etc/GMT | Alnylam shares fall on Europe patent dispute loss (AP) | | Fri, 11 Jul 2008 18:11:48 Etc/GMT | Movers roundup: Tuesday Morning, Teva Pharma (AP) | | Fri, 11 Jul 2008 17:26:37 Etc/GMT | Feuerstein's Biotech-Stock Mailbag: Acadia (at TheStreet.com) | | Thu, 10 Jul 2008 21:00:00 Etc/GMT | Alnylam Provides Update on "Glover" Patent (Business Wire) | | Wed, 2 Jul 2008 21:39:01 Etc/GMT | New approach offers chance to finally kill herpes (at Reuters) | | Tue, 24 Jun 2008 15:00:00 Etc/GMT | Regulus Therapeutics Selected for Fierce 15 Top Biotech Companies (Business Wire) | | Thu, 19 Jun 2008 20:56:04 Etc/GMT | Health Winners & Losers: Gilead (at TheStreet.com) | | Thu, 19 Jun 2008 18:27:12 Etc/GMT | Movers roundup: Usana Health, Healthways (AP) | | Thu, 19 Jun 2008 16:15:08 Etc/GMT | Alnylam inks RNAi alliance with Japanese biotech (at bizjournals.com) | News provided by Yahoo! Finance |
|
